Symbiotec Pharmalab is scheduled to finalise the basis of allotment for its ₹1,757-crore initial public offering after the mainboard issue received bids for 71.26 times the shares available.
The IPO opened on August 24 and closed on August 27 at a price band of ₹938 to ₹988 a share. A retail lot contained 15 shares, putting the minimum application at ₹14,820 at the upper price. The shares are proposed to list on the BSE and NSE on September 1.
How to check the allotment result
MUFG Intime India is the registrar to the issue. Once the company appears in the registrar’s active allotment list, applicants can search using PAN, application number, demat account or the other identifier permitted by the form. The official BSE IPO application page and NSE bid-verification service are additional ways to verify status.
Applicants should use only the registrar or exchange domain and should never disclose a trading password, UPI PIN or banking one-time code. Successful applications are followed by the credit of shares to the registered demat account; unsuccessful or partially successful applications trigger release of the relevant blocked amount according to the timetable.
Final subscription by category
The offer was subscribed 71.26 times overall. Qualified institutional buyers subscribed about 172.03 times their reserved portion, non-institutional investors 73.63 times and retail investors 12.96 times. The employee category was subscribed approximately 15.41 times.
These category figures measure bids relative to shares reserved for each group. They do not guarantee an allotment or a profitable listing, and applicants should not add category multiples together.
What Symbiotec Pharmalab does
The Indore-based pharmaceutical manufacturer focuses on specialised active pharmaceutical ingredients, including corticosteroids and steroid hormones. Its operations span development and manufacturing, and the company supplies regulated and other markets. The offer documents identify repayment or prepayment of certain borrowings and general corporate purposes among the uses for the fresh-issue proceeds.
Investors examining the company should also consider manufacturing concentration, regulatory compliance, customer exposure, raw-material supply and the fact that a substantial offer-for-sale component does not provide new capital to the business.
GMP is not an official listing estimate
An unofficial tracker quoted a grey market premium of about ₹315 on August 26, implying an informal estimate above the ₹988 upper price. The figure was already capable of changing before allotment and listing. GMP transactions occur outside the recognised exchanges and are neither endorsed by SEBI nor guaranteed to reflect the opening trade.
Applicants should distinguish the official issue price, allotment status and exchange listing from grey-market discussion. Subscription demand can support market interest, but it does not remove the possibility of a weak debut or later price decline. This article is informational and does not constitute investment advice.
